April 13, 1989: GanMed Biotechnical is founded as a small research lab in Baltimore, Maryland

1990: Work begins on a novel rDNA leukemia treatment

1990: Federal permission is granted to fast track most of GanMed's products through the approval process

1991: GanMed announces construction of its new facility in Washington, DC

1991: GanMed marks its second year of rapid financial growth

1992: GanMed Biotechnical moves from the Maryland offices to its new facilities in Wachington, DC

1993: GanMed's rDNA leukemia treatment, ChemaCyte, receives approval for marketing

1993: Sedgwick Pharma purchases world marketing rights for ChemaCyte

1994: GanMed Biotechnical maintains record sales for the fifth consecutive year

1995: GanMed creates the first fully humanized monoclonal antibody able to be mass produced in a cost-effective manner

1995: GanMed Biotechnical announces third quarter profits that far exceed company expectations

1996: Vesaflu, an rDNA flu treatment, receives final approval and is sold to LunaPharma of Scranton, Pennsylvania

1997: Zeogena becomes the first monoclonal treatment for prenatally diagnosed Down's syndrome

1998: GanMed posts its eighth consecutive year of sales growth

2001: GanMed Biotechnical announces IPO of 5,000,000 shares of common stock

Recent News:

11/05/2001

GanMed Biotechnical Announces IPO of 5,000,000 Shares of Common Stock

Washington, DC (November 5, 2001) - GanMed Biotechnical ("GanMed") announced today the initial public offering of 5,000,000 shares of its Common Stock at a price of $10.00 per share. All 5,000,000 shares are being offered and sold by GanMed. The offering is being co-managed by an underwriting group including Shiveley Financial and Northeast Financial Associates of Delaware. The Company has granted the underwriters a 30-day option to purchase up to 750,000 additional shares to cover over-allotments, if any. If the underwriters exercise their over-allotment option in full, GanMed will receive approximately $51,975,000 in net proceeds. The Company's common stock will be trading on the NASDAQ under the ticker symbol "GNMD".

Copies of the final prospectus relating to these securities may be obtained from Shiveley Financial or Northeast Financial Associates of Delaware.





About GanMed--Jobs @ GanMed--Home--GanMed News
Webmaster@GanMed.com